COMPASS PATHWAYS PLC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 86.51K shares, a 2182.59% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 4.24K shares, a 346.42% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 33.69K shares, a 12.73% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 125.08K shares, a 124.45% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 925.18K shares, a 388.96% increase from fiscal 2024.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 189.21K shares, a 13.44% increase from fiscal 2023.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 166.80K shares, a 63.95% decline from fiscal 2022.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 462.72K shares, a 62.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 925.18K shares 10-K · filed 2026-03-24 | |
| 2024-12-31 | 189.21K shares 10-K · filed 2025-02-27 | |
| 2024-03-31 | 86.51K shares 10-Q · filed 2024-05-08 | 249.52K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 4.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 166.80K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 33.69K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 163.51K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 125.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 159.71K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 3.79K shares 10-Q · filed 2023-05-11 | 90.35K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 950.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 462.72K shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 29.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 690.57K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | 55.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 743.82K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | 376.16K shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 228.79K shares derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | 1.24M shares 10-K · filed 2023-02-28 |
| 2021-09-30 | 83.14K shares derived: 6-K 9 month − 6-K 6 month · filed 2021-11-09 | |
| 2020-12-31 | 429.93K shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |